Climb Bio (CLYM) stock: insider trades, news & valuation
Net sellingShare price and insider trades
Climb Bio insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $780K and 2 sold $2.7M of CLYM stock on the open market.
Get emailed when insiders cluster-buy stocks like CLYM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CLYM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $1.4M | 1 |
| Q2 2026 | — | 0 | $407K | 1 |
| Q1 2026 | $25K | 1 | $879K | 4 |
| Q4 2025 | $755K | 2 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Climb Bio, Inc. insiders reported open-market purchases totaling $780K, while 2 insiders reported sales totaling $2.7M. Among insiders with enough purchase history to measure, Peter Kolchinsky (Director) has the highest Insider Score at 99. 6 of 6 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 17SEC | Stephen Basil ThomasDirector | Sell Plan | 100,000467,969 held (−18%) | $13.67 | $1.4M | -19.5% | — |
| Jun 30SEC | Aoife BrennanCEO, President | Sell Plan | 30,90287,731 held (−26%) | $13.17 | $407K | -16.5% | — |
| Feb 27SEC | Stephen Basil ThomasDirector | Sell Plan | 33,687170,970 held (−16%) | $7.00 | $236K | +57.1% | — |
| Feb 27SEC | Stephen Basil ThomasDirector | Sell Plan | 16,313154,657 held (−10%) | $7.01 | $114K | +56.9% | — |
| Feb 17SEC | Stephen Basil ThomasDirector | Sell Plan | 90,000214,657 held (−30%) | $5.23 | $471K | +110.3% | — |
| Feb 17SEC | Stephen Basil ThomasDirector | Sell Plan | 10,000204,657 held (−5%) | $5.81 | $58K | +89.3% | — |
| Jan 7SEC | Ra Capital Healthcare Fund LpDirector | Buy | 7,1113,403,429 held (+0%) | $3.50 | $25K | +214.3% | 98 |
| Dec 15SEC | Peter KolchinskyDirector | Buy | 213,0993,294,856 held (+7%) | $2.18 | $465K | +404.6% | 99 |
| Dec 15SEC | Peter KolchinskyDirector | Buy | 101,4623,396,318 held (+3%) | $2.86 | $290K | +284.6% | 99 |
Insiders at Climb Bio, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Peter KolchinskyDirector | $755K | — | Dec 15, 2025 | 99 |
| Stephen Basil ThomasDirector | — | $2.2M | Sep 17, 2026 | — |
| Aoife BrennanCEO, President | — | $407K | Jun 30, 2026 | — |
| Ra Capital Healthcare Fund LpDirector | $25K | — | Jan 7, 2026 | 98 |
CLYM stock: common questions
Are Climb Bio, Inc. insiders buying CLYM stock?
In the past 12 months, 2 insiders reported open-market purchases of CLYM worth $780K. The latest was Director Ra Capital Healthcare Fund Lp bought $25K of CLYM at $3.50 — first open-market purchase in our records.
Are Climb Bio, Inc. insiders selling CLYM stock?
2 insiders reported sales worth $2.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CLYM's 52-week range?
Over the past year CLYM has traded between $1.64 and $17.84. It last closed at $11.00 on Oct 9, 2026.